Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European blood safety techs market set to exceed $520m by 2013

This article was originally published in Clinica

Executive Summary

Europe’s blood pathogen inactivation market is set to reach an estimated $521.5m by 2013, according to analysts Frost & Sullivan, from around $238.5m in 2009. The impact of “remarkable advances” in the prevention of transfusion-transmitted diseases has been slowed by an excessively reactive approach to transfusion risk, argue the authors of a report called European Blood Pathogen Inactivation Market, published today. However, the continued emergence and re-emergence of transfusion-transmitted infections promises “very good potential for growth”, they claim.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts